Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Plus Grants Program

University of British Columbia

$12,500.00

Antibody formulation for the gastrointestinal tract

EF 2017-18

Résumé
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. Thisproject proposes to develop antibody formulations appropriate for application in the GI tract. The developmentof a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.
Programme
Engage Plus Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
517780-2017
Name nom
Accili, Eric
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Antibody formulation for the gastrointestinal tract
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. Thisproject proposes to develop antibody formulations appropriate for application in the GI tract. The developmentof a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.